The role of CD95 signaling in studies reporting tumor-promoting or tumor-suppressing CD95 signaling in glioblastoma was inferred upon pharmacologic targeting, RNAi-mediated gene downregulation, ectopic CD95 or CD95L expression, or the comparative analysis of tumor cell populations segregated based on CD95 expression levels. This evidence concerns the gene FASLG and glioblastoma.